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Early mammalian embryogenesis is controlled by mechanisms that 
govern the balance between pluripotency and differentiation. 
Expression of early lineage-specific genes varies substantially between 
species1–3, with implications for developmental control and stem cell 
derivation. However, the mechanisms that pattern the human embryo 
are unclear, because of a lack of methods to efficiently perturb gene 
expression of early lineage specifiers in this species.
Recent advances in genome editing using the CRISPR (clustered 
regularly interspaced, short palindromic repeat)–Cas (CRISPR-
associated) system have greatly increased the efficiency of genetic 
 modification. The Streptococcus pyogenes Cas9 endonuclease is 
guided to homologous DNA sequences via a single-guide RNA (sgRNA) 
whereby it induces double strand breaks (DSBs) at the target site4. Endo-
genous DNA repair mechanisms function to resolve the DSBs, including 
error-prone non-homologous or micro- homology-mediated end joining, 
which can lead to insertions or deletions (indels) of nucleotides that can 
result in the null mutation of the target gene. CRISPR–Cas9-mediated 
editing has been attempted in abnormally  fertilized tripronuclear human 
zygotes and a limited number of  normally fertilized human zygotes, with 
variable success5–8. To determine whether CRISPR–Cas9 can be used 
to understand gene function in human preimplantation development, 
we chose to target POU5F1, a gene encoding the developmental regu-
lator OCT4, as a proof-of- principle. Zygotic POU5F1 is thought to be 
first transcribed at the four- to eight-cell stage coincident with embryo 
genome activation (EGA), and OCT4 protein is not detectable until 
approximately the eight-cell stage2,3. OCT4 perturbation would be pre-
dicted to cause a clear developmental phenotype based on studies in the 
mouse9,10 and human embryonic stem (ES) cells11.
By using an inducible human ES cell-based CRISPR–Cas9 system 
and optimizing mouse zygote microinjection techniques, we have 
identified conditions that allowed us to target POU5F1 efficiently and 
precisely in human zygotes. Live embryo imaging revealed that while 
OCT4-targeted human embryos initiate blastocyst formation, the inner 
cell mass (ICM) forms poorly, and embryos subsequently  collapse. 
Mutations affecting POU5F1 in human blastocysts are associated with 
the downregulation of genes associated with all three preimplanta-
tion lineages, including NANOG (epiblast), GATA2 (trophectoderm) 
and GATA4 (primitive endoderm). By contrast, in OCT4-null mouse 
blastocysts, genes such as Nanog continue to be expressed in the ICM. 
The insights gained from these investigations advance our understanding 
of human development and suggest that OCT4 has an earlier role in 
the progression of the human blastocyst compared to the mouse, and 
therefore that there are distinct mechanisms of lineage specification 
between these species.
Selection of an sgRNA targeting POU5F1
To target POU5F1, we selected four sgRNAs using a standard in  silico 
prediction tool12: two targeting the exon encoding the N-terminal 
domain of OCT4 (sgRNA1-1 and sgRNA1-2), one targeting the 
exon encoding the conserved DNA-binding POU homeodomain13,14 
(sgRNA2b) and one targeting the end of the POU domain and the 
start of the C-terminal domain (sgRNA4) (Extended Data Fig. 1a). 
To screen candidate sgRNAs, we took advantage of human ES cells as 
an unlimited resource that reflects the cellular context of the human 
preimplantation embryo. We engineered isogenic human ES cells 
constitutively expressing the Cas9 gene, together with a tetracycline- 
inducible sgRNA11 (Fig. 1a), thereby allowing comparative assessment 
of sgRNA activities.
Cells were collected every day for five days for flow cytometry analysis, 
which revealed that induction of each of the sgRNAs in human 
ES cells imposed remarkably different temporal effects on OCT4 
 protein expression (Extended Data Fig. 1b). sgRNA2b was the most 
Despite their fundamental biological and clinical importance, the molecular mechanisms that regulate the first cell 
fate decisions in the human embryo are not well understood. Here we use CRISPR–Cas9-mediated genome editing to 
investigate the function of the pluripotency transcription factor OCT4 during human embryogenesis. We identified an 
efficient OCT4-targeting guide RNA using an inducible human embryonic stem cell-based system and microinjection of 
mouse zygotes. Using these refined methods, we efficiently and specifically targeted the gene encoding OCT4 (POU5F1) 
in diploid human zygotes and found that blastocyst development was compromised. Transcriptomics analysis revealed 
that, in POU5F1-null cells, gene expression was downregulated not only for extra-embryonic trophectoderm genes, such 
as CDX2, but also for regulators of the pluripotent epiblast, including NANOG. By contrast, Pou5f1-null mouse embryos 
maintained the expression of orthologous genes, and blastocyst development was established, but maintenance was 
compromised. We conclude that CRISPR–Cas9-mediated genome editing is a powerful method for investigating gene 
function in the context of human development.
1Human Embryo and Stem Cell Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK. 2NIHR Cambridge Biomedical Research Centre hIPSC Core Facility, Department of 
Surgery, University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0SZ, UK. 3Sex Chromosome Biology Laboratory, The Francis Crick Institute, London NW1 1AT, UK. 4Nuffield 
Department of Obstetrics and Gynaecology, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, UK. 5Bourn Hall Clinic, Bourn, Cambridge CB23 2TN, UK. 6Department of Chemistry, 
Seoul National University, Seoul 151-747, South Korea. 7Bioinformatics Facility, The Francis Crick Institute, London NW1 1AT, UK. 8Center for Genome Engineering, Institute for Basic Science, 
Daejeon 34047, South Korea. 9Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK. 10Wellcome Trust and MRC Cambridge Stem Cell Institute and 
Biomedical Research Centre, Anne McLaren Laboratory, Department of Surgery, University of Cambridge, Cambridge CB2 0SZ, UK. †Present address: Department of Pathology, University of 
Washington, Seattle, Washington 98109, USA.
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
ArticlereSeArcH
6 8  |  N A t U r e  |  V o L  5 5 0  |  5  o c t o b e r  2 0 1 7
efficient at rapidly causing loss of OCT4 protein expression, with 
only 15.6% of cells retaining detectable OCT4 by day 5 of induction. 
Immunofluorescence analysis following sgRNA2b induction confirmed 
the efficient loss of OCT4 expression (Fig. 1b, Extended Data Fig. 2a). 
Conversely, in human ES cells induced to express sgRNAs 1-1, 1-2 or 4, 
43.7%, 70.5% and 51.7% of cells retained OCT4 expression at the 
equivalent time, respectively (Extended Data Fig. 1b). To identify the 
transcriptional consequences of OCT4 depletion, we performed quanti-
tative PCR with reverse transcription (qRT–PCR) and RNA sequencing 
(RNA-seq) analysis on induced and non-induced sgRNA2b- expressing 
human ES cells (Extended Data Figs 1c, d and 2b). Induction of 
sgRNA2b resulted in downregulation of pluripotency genes such as 
NANOG, ETS1 and DPPA3, consistent with OCT4 depletion causing 
exit from self-renewal. Furthermore, the differentiation-associated 
genes PAX6, SOX17, SIX3, GATA2 and SOX9 were upregulated after 
induction of sgRNA2b, suggesting that OCT4 normally restrains 
differentiation (Extended Data Figs 1c, d and 2a, b).
Analysing POU5F1 targeting specificity
To compare the on-target editing efficiencies and mutation spectrums 
induced by candidate sgRNAs, we performed a time-course genotypic 
analysis on cells collected across four days after sgRNA induction. 
Targeted deep sequencing of the on-target site revealed indels from as 
early as 24 h after induction of sgRNA2b, but not until 48 h after induc-
tion of sgRNAs1-1, 1-2 or 4 (Fig. 1c). sgRNA2b-induced indels most 
commonly comprised a 2-bp deletion upstream of the protospacer- 
adjacent motif (PAM) site leading to a frameshift mutation and a 
 premature stop codon (Extended Data Fig. 3), consistent with the loss 
of OCT4 protein expression.
We evaluated putative off-target sites identified by their sequence 
similarity to the seed region of sgRNA2b (Extended Data Fig. 4a, b). 
We did not observe off-target indels in sgRNA2b-induced human ES 
cells, nor any sequence alterations above background PCR error rates 
observed in control human ES cell lines. In parallel, we performed a 
genome-wide unbiased evaluation of off-target events using Digenome-
seq (Extended Data Fig. 4c). Targeted deep sequencing across the 
experimentally determined putative off-target sites revealed that 
indels had occurred only at the on-target site (Extended Data Fig. 4d). 
Furthermore, we used the WebLogo program to determine the most 
frequent sequences associated with putative sites identified from 
Digenome-seq15,16 (Extended Data Fig. 4e). Deep sequencing at these 
sites also confirmed that no off-target events had occurred (Extended 
Data Fig. 4f). In all, owing to both its efficient mutageni city and its high 
on-target specificity, sgRNA2b appeared the most promising.
sgRNA activity in mouse embryos
We used published sgRNA and Cas9 mRNA zygote microinjection 
conditions17 to further assess sgRNA activity and optimize microinjec-
tion methodologies in mouse zygotes. As it has been shown that OCT4-
null mouse blastocysts lack expression of the primitive endoderm 
marker SOX17 owing to a cell-autonomous requirement for FGF4 and 
MAPK signalling9,18, we used the absence of both OCT4 and SOX17 
immunostaining to identify OCT4-deficient embryos (Fig. 1d). This 
OCT4-null phenotype was observed in 54% of embryos injected with 
Cas9 mRNA and sgRNA2b, and in 0%, 10% or 3% of embryos injected 
with Cas9 mRNA and sgRNA1-1, sgRNA1-2 or sgRNA4, respectively 
(Fig. 1e). These data confirm that sgRNA2b is superior to the other 
tested sgRNAs at inducing null mutations in both mouse embryos and 
human ES cells. We next tested a greater range of Cas9 mRNA and 
sgRNA concentrations to identify conditions that could enhance rates 
of mutagenesis (Extended Data Fig. 5a). We confirmed that the previ-
ously reported concentrations of 100 ng μ l−1 Cas9 mRNA and 50 ng μ l−1 
sgRNA17 were optimal for inducing an OCT4-null phenotype.
It has been suggested that microinjection of sgRNA and Cas9 ribo-
nucleoprotein complexes may reduce mosaicism and allelic complexity 
by bypassing the requirement for Cas9 translation and sgRNA–Cas9 
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Figure 1 | Screening sgRNAs targeting OCT4 in optimized inducible 
CRISPR–Cas9 knockout human ES cells and mouse embryos.  
a, Schematic of strategy used to induce sgRNA expression in  
human ES cells. The CAG promoter drives constitutive expression  
of the Cas9 gene as well as the tetracycline-responsive repressor (tetR).  
The inducible H1-TO promoter drives expression of each sgRNA  
in the presence of tetracycline (TET). The two transgenic cassettes  
are each targeted to one of the AAVS1 genomic safe harbour loci using 
zinc-finger nucleases (ZFN). TO, tetracycline-responsive operator.  
b, Immunofluorescence analysis of OCT4 (red) or PAX6 (green) and  
DAPI nuclear staining (blue) expression in human ES cells after 4 days  
of sgRNA2b induction (+ Tet) or in uninduced (No Tet) control human  
ES cells. Scale bars, 100 μ m. c, Quantification of indel mutations  
detected at each sgRNA on-target site after 4 days of sgRNA2b induction 
(+ Tet). n = 2 (sgRNA1-1); n = 3 (sgRNA1-2, sgRNA2b or sgRNA4 clones). 
One-way ANOVA compared to uninduced human ES cells.  
d, Immunofluorescence analysis for OCT4 (red), SOX17 (green)  
and DAPI nuclear staining (blue) in control, OCT4-null or mosaic  
mouse blastocysts 4 days after zygote microinjection. Panels that show 
individual proteins are in grey; coloured labels relate to merged panels 
only. Scale bars, 100 μ m. e, Quantification of proportions of OCT4-null, 
mosaic or wild-type mouse blastocysts after microinjection of Cas9 mRNA 
plus sgRNA1-1, sgRNA1-2, sgRNA2b or sgRNA4, or uninjected controls. 
Chi-squared test. Data are mean ± s.d. f, Quantification of proportions of 
OCT4-null, mosaic or wild-type mouse blastocysts after microinjection 
of the sgRNA2b–Cas9 ribonucleoprotein complex at concentrations 
indicated. Chi-squared test. Data are mean ± s.d. g, Comparison of 
mutation spectrums after targeting mouse embryos with sgRNA2b plus 
Cas9 mRNA or protein. Data are proportions of unique indels observed. 
Chi-squared test. * P < 0.05; * * P < 0.01; * * * * P < 0.0001.
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 complex formation in embryos19,20. To test this, we microinjected mouse 
pronuclear zygotes with preassembled ribonucleoprotein complexes 
containing varying concentrations of Cas9 protein (20–200 ng μ l−1) 
and sgRNA2b (20–100 ng μ l−1; Fig. 1f and Extended Data Fig. 5b). 
Immunofluorescence analysis revealed that the sgRNA–Cas9 complex 
was superior to Cas9 mRNA in causing loss of both OCT4 and SOX17, 
and that the optimal concentration comprised 50 ng μ l−1 Cas9 protein 
and 25 ng μ l−1 sgRNA (Fig. 1f). Notably, MiSeq analysis demonstrated 
that 83% of blastocysts derived from sgRNA2b–Cas9 complex micro-
injections had four or fewer different types of indels (Fig. 1g), suggesting 
that editing occurred before or at the two-cell stage. By contrast, 
only 53% of embryos microinjected with sgRNA2b and Cas9 mRNA 
exhibited this range of indels. Furthermore, a greater proportion of 
blastocysts that formed after sgRNA2b and Cas9 mRNA micro injection 
had six or more different types of detectable indels (42%) compared to 
those that formed after microinjection of the sgRNA2b–Cas9 complex 
(8%). This increased mutational spectrum suggests that, following 
Cas9 mRNA injection, DNA editing occurred between the three- and 
four-cell stages. Consistent with previous reports21, we observed a 
 stereotypic pattern in the types of indels detected in  independently 
 targeted embryos, including the representative 28-bp deletion 
(Extended Data Fig. 5c), which was distinct from those induced in 
human ES cells.
As well as lacking SOX17 and OCT4 expression, mouse embryos 
microinjected with the sgRNA2b–Cas9 complex recapitulated other 
reported OCT4-null phenotypes, such as downregulation of PDGFRA, 
SOX7, GATA6 and GATA4 in the primitive endoderm (Extended Data 
Fig. 5d). Consistent with the role of OCT4 in repressing trophectoderm 
genes9, the few ICM cells that could be detected in sgRNA2b–Cas9 
microinjected embryos expressed CDX2 ectopically (Extended Data 
Fig. 5d). When plated in mouse ES cell derivation conditions, these 
embryos failed to generate ICM outgrowths, and instead differenti-
ated into trophoblast-like cells (Extended Data Fig. 5e). By contrast, 
blastocysts derived from non-injected embryos formed ICM 
outgrowths in most instances, as did blastocysts from embryos micro-
injected with Cas9 protein alone or an sgRNA–Cas9 complex targeting 
Dmc1 (a gene not essential for preimplantation development). Having 
thus determined sgRNA2b to be an efficient and specific guide capable 
of generating a null mutation of POU5F1 or Pou5f1 in human ES cells 
and mouse preimplantation embryos, respectively, we next used this 
guide together with our optimized microinjection technique to target 
POU5F1 in human preimplantation embryos.
Targeting POU5F1 in human preimplantation embryos
To test whether OCT4 is required in human embryos, we performed 
CRISPR–Cas9 editing on thawed in vitro fertilized (IVF) zygotes that 
were donated as surplus to infertility treatment. We microinjected 
37 zygotes with the sgRNA2b–Cas9 ribonucleoprotein complex 
(Supplementary Video 1), and 17 zygotes with Cas9 protein alone 
to control for the microinjection technique. Of the zygotes that were 
microinjected with sgRNA2b–Cas9, 30 embryos retained both pronuclei 
during microinjection, with pronuclear fading observed approximately 
6 h later and cytokinesis on average 5 h later (Supplementary Video 2). 
These timings are similar to those previously published22,23 and  indicate 
that microinjection was performed when the embryos were in S phase 
of the cell cycle (Fig. 2a). Genome editing by the ribonucleoprotein 
complex has been estimated24 to start after approximately 3 h in vitro 
and to persist for 12–24 h, so CRISPR–Cas9-induced DSBs are likely 
to be formed during late S phase or subsequently at G2 phase. In 
seven of the zygotes that were microinjected with sgRNA2b–Cas9, the 
pronuclei had already faded after thawing, showing that they had 
exited S phase and were undergoing syngamy. These embryos conse-
quently underwent cell division approximately 3 h after microinjection. 
In these embryos, editing is likely to have occurred during the G1 phase 
of the next cell cycle, at the two-cell stage (Fig. 2a), which would 
promote mosaicism.
Time-lapse microscopy of the embryos showed that the timings of 
cleavage divisions following pronuclear fading were similar between 
embryos microinjected with Cas9 protein or sgRNA2b–Cas9 (Fig. 2b, c). 
By the eight-cell stage, cleavage arrest was observed in 62% (23 out 
of 37) of sgRNA2b–Cas9-microinjected embryos compared to 53% 
(9 out of 17) of Cas9-microinjected control embryos (Fig. 2d). As 
develop mental arrest at the onset of EGA at the eight-cell stage 
 correlates strongly with aneuploidy in IVF embryos25, we also sought 
to determine embryo karyotypes. We performed low-pass whole- 
genome sequencing, which has been shown to accurately estimate gross 
chromosome anomalies26. We collected blastomeres from sgRNA2b–
Cas9-microinjected embryos arrested up to the eight-cell stage and 
detected chromosomal loss or gain in 83% (five out of six) of these 
embryos (Extended Data Fig. 6a), which is consistent with rates reported 
by preimplantation genetic screening26,27. Trophectoderm biopsies of a 
subset of blastocysts that developed following sgRNA2b–Cas9 micro-
injection showed that 60% (three out of five) were euploid (Fig. 2e, 
Extended Data Fig. 6a). The other two blastocysts  exhibited karyotypic 
abnormali ties, including the loss of chromosome 16 (Extended Data 
Fig. 6b), an abnormality frequently observed in human  preimplantation 
embryos and thus likely to be unrelated to targeting25. In the Cas9-
microinjected control group, 57% (four out of seven) of blastocysts were 
euploid, and aneuploidies were observed in the remaining three blasto-
cysts, including the loss of chromosome 14 in two sibling-matched control 
embryos, and the gain of chromosome 15 and 18 (Fig. 2e, Extended Data 
Fig. 6a, b). Altogether, these data suggest that CRISPR–Cas9 targeting 
does not increase the rate of karyotypic anomalies in human embryos.
Forty-seven per cent (8 out of 17) of Cas9-microinjected control 
embryos developed to the blastocyst stage, a rate equivalent to those 
of uninjected controls28, suggesting that the microinjection technique 
did not affect embryo viability (Fig. 2d). However, significantly fewer of 
the sgRNA2b–Cas9-microinjected embryos—only 19% (7 out of 37)—
developed to the blastocyst stage (Fig. 2d, P = 0.03). The blastocysts 
that formed following sgRNA2b–Cas9 protein microinjection were of 
variable quality (Extended Data Fig. 6c). Although all blastocysts had 
a discernible blastocoel cavity, only some possessed a small compact 
ICM (Extended Data Fig. 6c), and all retained a thick zona pellucida, in 
contrast to Cas9-microinjected controls. Embryos arising from zygotes 
microinjected with sgRNA2b–Cas9 also went through iterative cycles 
of expanding and initiating blastocyst formation and then collapsing, 
until some embryos ultimately degenerated (Supplementary Videos 2 
and 3). These findings suggest that targeting OCT4 in human embryos 
reduces both viability and quality of blastocysts.
To measure on-target editing efficiency, we performed targeted deep 
and/or Sanger sequencing of separate individual cells microdissected 
from sgRNA2b–Cas9-microinjected embryos arrested before the 
eight-cell stage, and found indels at the POU5F1 on-target site in 71% 
(five out of seven) of embryos (Fig. 3a, purple line). The most frequently 
observed indels in sgRNA2b–Cas9-microinjected embryos were the 
2-bp and 3-bp deletions that were observed in the sgRNA2b-induced 
human ES cells (Fig. 3b, Extended Data Fig. 7a, b). This finding indicates 
that human ES cells can be used not only to screen sgRNA efficiency, 
but also to predict the in vivo mutation spectrum induced by CRISPR–
Cas9-mediated genome editing. We also detected larger POU5F1 
 deletions in the human embryos than in human ES cells, similar to 
our observations in mouse embryos (Fig. 3b, Extended Data Fig. 7a, b). 
Furthermore, targeted deep and/or Sanger sequencing in edited cells 
demonstrated that off-target mutations were undetectable above 
background PCR error rates, confirming the specificity of the sgRNA 
(Extended Data Fig. 7c, d).
We next assessed mutational signatures in more developmentally 
advanced embryos, after EGA. Notably, we confirmed that on- 
target editing had occurred in eight out of eight sgRNA2b–Cas9-
microinjected embryos analysed from the eight-cell to the blastocyst 
stage (Fig. 3a, green line). However, these embryos invariably retained 
wild-type copies of the POU5F1 allele in at least one cell (Fig. 3a). 
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In sgRNA2b–Cas9-microinjected human embryos, OCT4 protein 
expression was downregulated in most cleavage-stage cells and unde-
tectable above background in others, confirming the high efficiency of 
editing (Fig. 3c, Extended Data Fig. 8a). However, we were able to iden-
tify at least one cell that had nuclear OCT4 staining above background 
levels in all cases (Fig. 3c, Extended Data Fig. 8a). Moreover, despite 
a significant reduction in cell number (P = 0.001), blastocyst-stage 
embryos also retained OCT4 expression in a subset of cells (Fig. 3d, 
e, Extended Data Fig. 8b, c). These findings suggest that POU5F1 tar-
geting efficiency is high, and that only embryos with partial OCT4 
expression are able to progress to the blastocyst stage.
To determine whether there is a high degree of editing in embryos 
before the onset of OCT4 expression, we microinjected four additional 
human embryos with the sgRNA2b–Cas9 complex and stopped their 
development before the eight-cell stage. One-hundred per cent (four 
out of four) of these embryos had detectable indels, with two embryos 
lacking wild-type POU5F1 alleles (Fig. 3a, black line). In one embryo, 
editing occurred in all blastomeres, although one blastomere retained 
one copy of the wild-type allele. In another embryo, although four 
out of five blastomeres had been edited, one blastomere retained both 
copies of the wild-type allele. Together with the cleavage-arrested 
embryos above, these data show that in 45% (five out of eleven) of 
cleavage stage embryos (either stopped or developmentally arrested), 
all of the cells analysed from each embryo had no detectable POU5F1 
wild-type alleles, indicating high rates of editing. In addition, these data 
suggest that OCT4 has an unexpectedly earlier function in humans 
than in mice, before blastocyst formation.
Loss of OCT4 associated with gene mis-expression
To identify globally which genes might be affected by the loss of OCT4, 
we microdissected single cells from microinjected embryos at the 
blastocyst stage. We adapted a method to isolate both RNA and 
DNA from single cells29 in order to perform RNA-seq and targeted 
deep or Sanger sequencing of on-target and putative off-target sites. 
Principal component analysis showed that cells from sgRNA2b–Cas9-
microinjected human blastocysts clustered distinctly from those 
derived from Cas9-microinjected controls (Fig. 4a). Notably, the  cluster 
from sgRNA2b–Cas9-microinjected embryos contained not only cells 
that were homozygous null mutant for POU5F1, but also those that 
were wild-type or heterozygous. This finding suggests that loss of 
POU5F1 may impose non-cell autonomous effects on gene  expression 
in neighbouring wild-type or heterozygous cells.
Differential gene expression analysis indicated that the genes that 
were most highly mis-expressed in the sgRNA2b–Cas9-targeted human 
blastocysts (compared to the Cas9 controls) included those that we 
 previously identified as highly enriched in the epiblast, including 
NANOG, KLF17, DPPA5, ETV4, TDGF1 and VENTX (Extended Data 
Fig. 9a, Supplementary Table 1). Immunofluorescence analysis con-
firmed that even in cells that retained OCT4, the expression of NANOG 
was absent (Fig. 4b, Extended Data Fig. 8c). In striking contrast, OCT4-
null mouse blastocysts maintained Nanog expression in the ICM 
(Fig. 4b, Extended Data Fig. 8d, e), as previously reported9,18.
In OCT4-null cells, several trophectoderm-associated genes were also 
downregulated, including CDX2, HAND1, DLX3, TEAD3, PLAC8 and 
GATA2 (Extended Data Fig. 9a, Supplementary Table 1). We  confirmed 
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Figure 2 | The developmental potential of human embryos following 
CRISPR–Cas9-mediated genome editing. a, Schematic of the first cell 
division in human embryos and time of microinjection. PN, pronuclei; 
PNF, pronuclear fading. b, Representative human embryo at each 
developmental stage analysed. B, blastocyst; SB, start of blastocyst 
formation; SC, start of cavitation. c, Morphokinetic analysis of 
human development after microinjection. Non-parametric two-tailed 
Kolmogorov–Smirnov test; NS, not significant. d, Kaplan–Meier survival 
curve of human embryos following microinjection of Cas9 protein or 
sgRNA2b–Cas9 ribonucleoprotein complex. Zygotic POU5F1 expression 
is initiated between the four- and eight-cell stages. Chi-squared test 
comparing the survival trend across time. * P < 0.05. e, Karyotype 
analysis by whole-genome sequencing of human blastocysts following 
microinjection of Cas9 protein or sgRNA2b–Cas9 ribonucleoprotein 
complex. Representative euploid embryos are shown.
© 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
Article reSeArcH
5  o c t o b e r  2 0 1 7  |  V o L  5 5 0  |  N A t U r e  |  7 1
loss of GATA2 protein expression in human sgRNA2b–Cas9-injected 
embryos (Fig. 4c, Extended Data Fig. 8f). Coupled with the failure to 
maintain a fully expanded blastocyst, this finding  suggests that the 
integrity of the trophectoderm may be compromised in OCT4-targeted 
embryos. To investigate this further, we performed immunofluores-
cence analysis for ZO-1, which incorporates into tight junctions during 
 trophectoderm formation. In sgRNA2b–Cas9-targeted human blasto-
cysts, ZO-1 expression was interrupted, patchy and diffuse  compared 
to the uniform network-like distribution in  uninjected control embryos 
(Fig. 4d). By contrast, in mouse Oct4-null embryos, expression of tro-
phectoderm markers such as Cdx2, Hand1 and Gata3 is upregulated9.
In addition, primitive endoderm markers such as GATA4 were 
downregulated in sgRNA2b–Cas9-microinjected embryos compared 
to Cas9 controls. Immunofluorescence analysis suggested that SOX17 
protein expression was also downregulated (Fig. 3d, Extended Data 
Fig. 8b). Moreover, we were surprised to observe ectopic expression 
of PAX6 in some cells from sgRNA2b–Cas9-edited human blastocysts 
(Extended Data Fig. 9a, Supplementary Table 1). The lack of expression 
of genes associated with all three lineages in the blastocysts suggests that 
OCT4-targeted embryos either failed to initiate the expression of these 
genes or downregulated their expression as development progressed. 
To determine whether the gene expression patterns in OCT4-targeted 
cells more closely resemble those of cells from earlier stages of human 
development, we integrated our data with a previously published dataset 
comprising all stages of human preimplantation development3,30  
(Fig. 4e, Extended Data Fig. 9b). This revealed that while cells from 
OCT4-targeted embryos were progressing towards the transcriptional 
state of the blastocyst, they were more dispersed and heterogeneous 
in their gene expression. Together, our data suggest that the integrity 
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Figure 3 | Genotypic characterization of OCT4-targeted human embryos. 
a, Proportion of POU5F1-null, heterozygous or wild-type (WT) cells in 
each human embryo. The number of separate individual cells analysed is 
indicated. Embryos 2, 5, 7 and 8 were microinjected with Cas9 protein as 
a control. All other embryos were microinjected with the sgRNA2b–Cas9 
ribonucleoprotein complex. The development of some embryos was 
stopped and they were removed from culture for analysis, while others were 
analysed following cleavage arrest. b, The types and relative proportions of 
indel mutations observed compared to all observable indel mutations within 
each human embryo. c, Immunofluorescence analysis for OCT4 (green) 
and DAPI nuclear staining (blue) in an uninjected control cleavage stage 
human embryo or an embryo that developed following sgRNA2b–Cas9 
microinjection (n = 5). Confocal z-section. Arrowhead, OCT4-expressing 
cell. Scale bars, 100 μ m. d, Immunofluorescence analysis for OCT4 
(green), SOX17 (red) and DAPI nuclear staining (blue) in an uninjected 
control human blastocyst (n = 3) or a blastocyst that developed following 
sgRNA2b–Cas9 microinjection (n = 3). Confocal z-section. Scale bars,  
100 μ m. e, Quantification of the number of DAPI- or OCT4-positive nuclei 
in uninjected control human blastocysts (n = 3) compared to blastocysts 
that developed following sgRNA2b–Cas9 microinjection (n = 5). One-tailed 
t-test. * * P < 0.01; * * * P < 0.001.
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downregulation. As a result, all lineages are negatively affected, pointing 
to a functional role for OCT4 in early human development.
Discussion
CRISPR–Cas9-mediated genome editing represents a  transformative 
method to evaluate the function of putative regulators of human 
 preimplantation development. We have demonstrated the impor-
tance of initially screening sgRNA efficiencies and mutagenic patterns 
before targeting in human embryos, as sgRNAs were not equivalently 
efficient in inducing POU5F1-null mutations despite scoring highly by 
in silico predictions. We have shown that OCT4 loss has different conse-
quences in human and mouse embryos, consistent with other  differences 
reported between these species. For example, pharmacological 
inhibition of FGF and downstream ERK signalling leads to ectopic 
expression of pluripotency factors in the mouse, but not the human at 
equivalent stages31,32.
Unexpectedly, our data suggest that OCT4 may be required earlier 
in human development than in mice, for instance during the  cleavage 
or morula stages, when OCT4 expression is initiated (Fig. 4f). As 
the mouse maternal–zygotic Pou5f1-null mutation phenocopies the 
 zygotic-null mutation9, it is unlikely that persistence of maternal tran-
scripts or proteins compensates for the loss of OCT4 expression, and 
any additional compensatory mechanisms that may be present in 
the mouse do not appear to be conserved in the regulation of human 
 development. The mis-expression of genes associated with all three 
blastocyst lineages in OCT4-targeted human blastocysts further 
 suggests that OCT4 may have an essential function before this stage. In 
the future, it would be informative to determine whether OCT4 muta-
tion leads to changes in gene expression before the blastocyst stage, 
which may explain the failure of blastocyst development. Alternatively, 
inducing POU5F1-null mutations in human embryos slightly later in 
development, following the onset of EGA, may bypass its earlier critical 
role and thereby delineate its function in the fully formed blastocyst.
Notably, CRISPR–Cas9-mediated genome editing does not appear 
to increase genomic instability or developmental arrest before EGA, 
suggesting that this method could be used to understand the function 
of other putative lineage specifiers. In future, a number of adaptations 
may provide further advantages. Co-injection of the CRISPR–Cas9 
components with sperm during intracytoplasmic sperm injection33 
might allow more time for targeting before the first cell division, 
further increasing editing efficiency. Indeed, this approach has been 
used recently in human embryos8. Introducing multiple sgRNAs might 
increase targeting efficiency, but may also increase the risk of off-target 
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Figure 4 | Phenotypic characterization of OCT4-targeted human 
embryos. a, Principal component analysis of single-cell RNA-seq 
data showing comparisons between the cells from human blastocysts 
that developed following microinjection of the sgRNA2b–Cas9 
ribonucleoprotein complex (filled shapes) and Cas9-microinjected 
controls (unfilled shapes). The genotype of each cell is distinguished by 
colour. Five samples failed repeated genotyping but the RNA quality is 
good and these are listed as Unknown. Each data point represents a single 
cell. b, Immunofluorescence analysis for OCT4 (green), NANOG (red) 
and DAPI nuclear staining (blue) in a human or a mouse uninjected 
control blastocyst or blastocyst that developed after sgRNA2b–Cas9 
microinjection (mouse: n = 7; human: n = 3). Confocal z-section. Scale 
bars, 100 μ m. c, Immunofluorescence analysis for OCT4 (green), GATA2 
(magenta) and DAPI nuclear staining (blue) in an uninjected control 
human blastocyst (n = 3) or in a blastocyst that developed following 
sgRNA2b–Cas9 microinjection (n = 3). Confocal projection. Scale 
bars, 100 μ m. d, Immunofluorescence analysis for OCT4 (green), ZO-1 
(magenta) and DAPI nuclear staining (blue) in an uninjected control 
human blastocyst (n = 2) or in a blastocyst that developed following 
sgRNA2b–Cas9 microinjection (n = 2). Confocal projection. Scale 
bars, 100 μ m. e, Principal component analysis of a previously published 
human single-cell RNA-seq dataset30 integrated with data from embryos 
microinjected with Cas9 protein or the sgRNA2b–Cas9 complex. Each 
point represents a single cell. f, Diagram summarizing the observations 
made in the study and their relationship to the onset of zygotic POU5F1 
expression.
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Supplementary Information is available in the online version of the paper.
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alongside a donor oligonucleotide complementary to the target locus 
and harbouring a premature stop codon should favour the generation 
of null mutations via homology-directed repair. This approach may 
not be straightforward, given that recent attempts to correct an abnor-
mal paternal gene variant were suggested to use the maternal allele 
for HDR rather than an introduced template8, although this requires 
further validation34. Targeting genes that are not essential for, or have 
a later or more specific role in, pre-implantation development will 
also inform our interpretation of the OCT4 phenotype. At present, 
we cannot be certain that the early developmental arrest is associated 
with the loss of OCT4 rather than some non-specific effect of inject-
ing both Cas9 and the sgRNA, as opposed to Cas9 alone. However, a 
previous study showed that human embryos in which a non-essential 
gene was targeted exhibited rates of blastocyst formation similar to con-
trols8. This suggests that the effects we see here are due to loss of OCT4. 
In summary, we have developed an optimized approach to  target OCT4 
in human embryos, thus suggesting that OCT4 has a  different function 
in humans than in mice. This proof of principle lays out a framework 
for future investigations that could transform our understanding of 
human biology, thereby leading to improvements in the establishment 
and therapeutic use of stem cells and in IVF treatments.
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Ethics statement. This study was approved by the UK Human Fertilisation and 
Embryology Authority (HFEA): research licence number 0162, and the Health 
Research Authority’s Research Ethics Committee (Cambridge Central reference 
number 16/EE/0067).
The process of licence approval entailed independent peer review along with 
consideration by the HFEA Licence Committee. Our research is compliant with 
the HFEA Code of Practice and has undergone inspections by the HFEA since 
the licence was granted. Research donors were recruited from patients at Bourn 
Hall clinic.
Informed consent was obtained from all couples that donated spare embryos 
following IVF treatment. Before giving consent, people donating embryos 
were provided with all of the necessary information about the research project, 
an opportunity to receive counselling and the conditions that apply within the 
licence and the HFEA Code of Practice. Specifically, patients signed a consent 
form  authorizing the use of genome editing techniques including CRISPR–
Cas9 on donated embryos. Donors were informed that after the embryos had 
been  genetically modified their development would be stopped before 14 days 
post- fertilization and that subsequent biochemical and genetic studies would be 
performed. Informed consent was also obtained from donors for all the results 
of these studies to be published in scientific journals. No financial inducements 
were offered for donation. Consent was not obtained to perform genetic tests on 
patients and no such tests were performed. The patient information sheets and 
consent document provided to patients are publicly available (https://www.crick.
ac.uk/research/a-z-researchers/researchers-k-o/kathy-niakan/hfea-licence/). 
Embryos surplus to the patient’s IVF treatment were donated cryopreserved and 
were transferred to the Francis Crick Institute where they were thawed and used 
in the research project.
Power analysis and data acquisition. The R statistical package pwr was used to 
determine the number of human embryos required to determine the function of 
OCT4 compared to microinjected controls. A two-sample t-test was performed to a 
significance level of P < 0.05. The effect size was 0.8, which assumes an observable 
difference between the CRISPR-injected and control embryos. The sample size was 
estimated to be 25 CRISPR-targeted embryos.
Unless stated otherwise, the experiments were not randomized and the investi-
gators were not blinded to allocation during experiments and outcome assessment.
sgRNA design to target POU5F1. So as not to lower the targeting efficiency, we 
determined whether the sgRNAs targeted polymorphic regions of the human 
genome. Most sgRNAs had a single nucleotide polymorphism (SNP) frequency 
of less than 0.1% in the human population, with the exception of the sgRNA 
targeting exon 4, which had an SNP frequency of 32% within the sgRNA target 
sequence as determined by the 1000 Genomes project35. We retained this sgRNA as 
it had the highest in silico score and overlapped with a site that has been previously 
shown in complementarity studies to be functionally required for pluripotency, 
suggesting that even an in-frame deletion would render a loss of function in the 
gene13. We also favoured the use of sgRNAs with sequence conservation of the 
PAM and sgRNA seed sequence (approximately 12-bp region proximal to the 
PAM sequence) that would allow us to determine efficiency in mouse embryos. 
In the case of high-scoring sgRNAs targeting exon 2d, there is no mouse equivalent 
sgRNA sequence that we could evaluate, and for exon 3, we could not design 
sgRNAs where the predicted cut site would be within the exon; these options were 
therefore excluded.
sgRNA production and ribonucleoprotein preparation. sgRNAs were prepared 
as previously described36. The sgRNA was cloned into the bicistronic expression 
vector px330 (Addgene; 4223037) using the Bbs1 restriction site. The sgRNA 
sequence from the correctly targeted px330 vector was amplified using the Q5 
hot start high fidelity DNA polymerase (NEB; M0493) and the PCR product was 
in vitro transcribed using the MEGAshortscript T7 kit (ThermoFisher Scientific; 
AM1354) and purified using the Zymo RNA Clean & Concentrator columns 
(Zymo Research; R1017). The sgRNA and Cas9 mRNA (TriLink Biotechnologies; 
L61256) and recombinant Cas9 protein (Toolgen; TGEN CP1) were individually 
re-suspended in RNase-free water, aliquoted and stored at − 80 °C until use. Prior 
to microinjection, the ribonucleoprotein complex was prepared by centrifuging the 
Cas9 protein for 1 min at 14,000 r.p.m. at 4 °C and transferring the supernatant to 
a fresh tube containing the sgRNA. This was incubated at 37 °C for 15 min, pulse 
spun and transferred to a fresh tube for microinjection.
Mouse zygote collection. Four- to eight-week-old (C57BL6 × CBA) F1 female 
mice were super-ovulated using injection of 5 IU of pregnant mare serum 
gonadotrophin (PMSG; Sigma-Aldrich). Forty-eight hours after PMSG injection, 
5 IU of human chorionic gonadotrophin (HCG; Sigma-Aldrich) was  administered. 
Superovulated females were set up for mating with eight-week-old or older 
(C57BL6 × CBA) F1 males. Mice were maintained on a 12 h light–dark cycle. 
Mouse zygotes were isolated in Global total with HEPES (LifeGlobal; LGTH-100) 
under mineral oil (Origio; ART-4008-5P) and cumulus cells were removed with 
hyaluronidase (Sigma-Aldrich; H4272). All animal research was performed in 
compliance with the UK Home Office Licence Number 70/8560.
Human embryo thaw. Human zygotes were thawed using Quinn’s Advantage 
thaw kit (Origio; ART-8016). Briefly, upon thawing the embryos were trans-
ferred to 3 ml of 0.5% sucrose thawing medium and incubated for 5 min at 37 °C, 
followed by 3 ml of 0.2% sucrose thawing medium for 10 min at 37 °C. The embryos 
were then washed through seven drops of diluent solution before culture. Human 
blastocysts were thawed using the Blast thaw kit (Origio; 10542010) following the 
manufacturer’s instructions.
Human and mouse microinjection and culture. Human and mouse embryo 
microinjections were performed in Global Total medium with HEPES under 
mineral oil on a heated stage with a holding pipette (Research Instruments) 
and a Femtojet 4i microinjection manipulator (Eppendorf) set at approximately 
40 injection pressure and 20 constant pressure. Embryos were microinjected with a 
mixture of Cas9 mRNA and sgRNA or the ribonulceoprotein complex back-filled 
into microfilament glass capillary injection needles (World Precision Instruments; 
TW100F-6) pulled using a pipette puller (Suter; P-97 micropipette puller). The 
microinjection procedure took ~ 15 min to complete.
Human or mouse embryos were cultured in drops of pre-equilibrated Global 
medium (LifeGlobal; LGGG-20) supplemented with 5 mg ml−1 protein supplement 
(LifeGlobal; LGPS-605) and overlaid with mineral oil (Origio; ART-4008-5P). Pre-
implantation embryos were incubated at 37 °C and 5.5% CO2 in an EmbryoScope+ 
time-lapse incubator (Vitrolife) for either 3–4 d (mouse) or 5–6 d (human).
Genomic DNA extraction and genotyping. Human ES cells were lysed using 
proteinase K digestion (10 μ g ml−1 in lysis buffer (100 mM Tris buffer pH 8.5, 5 mM 
EDTA, 0.2% SDS, 200 mM NaCl)) overnight at 37 °C. gDNA was extracted from the 
lysed cells using phenol:chloroform extraction followed by ethanol precipitation. 
For the time-course genotypic analysis, bulk cells were collected every 24 h and 
PCR products were amplified from the extraction genomic DNA. These products 
were used to generate multiplexed libraries for targeted amplicon sequencing by 
MiSeq according to the manufacturer’s instructions (Illumina).
Genomic DNA from fixed embryos (human and mouse) was isolated using 
the alkaline lysis method; 25 μ l of 50 mM NaOH was added to the sample and 
incubated at 95 °C for 5 min. Samples were neutralized by adding 2.5 μ l of 1 M 
Tris-HCL pH 8.0.
The Illustra Single Cell GenomiPhi DNA Amplification Kit (GE Healthcare 
Life Sciences; 29108039) was used according to manufacturer’s instructions to 
amplify gDNA from unfixed mouse blastocysts. DNA was purified by adding 30 μ l 
of 20 mM EDTA, 5 μ l of 3 M sodium acetate and 137 μ l ice cold ethanol. Tubes 
were mixed by inverting and centrifuged at 16,000g for 20 min. Supernatant was 
removed and DNA was washed in 100 μ l ice cold 70% ethanol by mixing and 
centrifuging for 5 min. DNA was resuspended by adding 20 μ l H2O and incubating 
for 20 min at 4 °C before mixing by gentle pipetting. These products were used to 
generate multiplexed libraries for targeted amplicon sequencing by MiSeq according 
to the manufacturer’s instructions (Illumina).
To genotype cells from unfixed Cas9 control or OCT4-targeted human embryos, 
genomic DNA was isolated from either an individual single cell (1-cell embryos) 
or following microdissection of multiple individual single-cell samples from each 
embryo or approximately five cells from trophectoderm biopsies. The samples 
were genotyped following whole genome amplification (WGA) using one of the 
following protocols:
(1) For the single cell samples used in the either the modified G&T-seq 
protocol29 or isolated solely for genotyping, genomic DNA was amplified using 
the REPLI-g Single Cell Kit (Qiagen; 150343) according to the manufacturer’s 
guidelines. The DNA samples were quantified using high-sensitivity Qubit assay. 
In preparation for Sanger sequencing and MiSeq analysis, the WGA DNA product 
was diluted 1:100 in nuclease-free water, and 2 μ l of this product was used as the 
template in a PCR reaction containing 25 μ l Phusion High Fidelity PCR Master Mix 
(New England Biolabs), 2.5 μ l 5 μ M forward primer, 2.5 μ l 5 μ M reverse primer and 
18 μ l nuclease-free water. Thermocycling settings used were as follows: 98 °C 30 s, 
35 cycles of 98 °C 10 s, 58 °C 30 s, 72 °C 30 s, and a final extension of 72 °C for 5 min. 
Gel electrophoresis confirmed that the size of the PCR product corresponded to 
the expected amplicon size. PCR amplicons were analysed by Sanger sequencing 
and indels were quantified by TIDE webtool38. Results of the TIDE analysis were 
also verified by manual visual inspection of the Sanger chromatograms. For MiSeq 
library preparation, quantification, pooling and denaturation were performed 
according to the manufacturer’s instructions (Illumina). PCR amplicons were 
cleaned using an equal volume of AMPure XP beads according to the manufac-
turer’s instructions (Beckman Coulter). Index PCR was performed using 10 μ l of 
cleaned amplicon, 12.5 μ l Q5 high fidelity 2X Master Mix (NEB; M0492S), 1.25 μ l 
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Nextera XT Index 1 primer and 1.25 μ l Nextera XT Index 2 primer (Nextera XT 
Index kit; FC‐131‐1001). The thermocycling parameters used were: 98 °C for 30 s, 
35 cycles of 98 °C for 10 s, optimized annealing temperature for 30 s, 72 °C for 30 s, 
and a final extension of 72 °C for 2 min. Index PCR was cleaned using equal volume 
of AMPure XP beads as described previously. Beads were rehydrated with 20 μ l 
nuclease-free water. Five microlitres of the index PCR product was run on a gel to 
identify any samples with over-abundance of primer dimers, which were subse-
quently subjected to gel size selection and extraction using QIAquick gel extrac-
tion kit (Qiagen; 28704). Index PCR products were quantified using QuantiFluor 
dsDNA system (Promega; E2670). The concentration was used to determine the 
dilution required to obtain a 5 μ M solution of each sample. Five microlitres of each 
sample was pooled and the library was spiked with 20% PhiX genomic control 
(Illumina; FC‐110‐3001). Sequencing generated paired-end (2 × 250-bp) dual 
indexed reads. After sequencing, reads were demultiplexed and stored as FASTQ 
files for downstream processing and analysis. The CRISPR Genome Analyser39 
or CRISPR Cas Analyser40 tools were used to align the reads and to determine 
the percentage of non-wild-type reads resulting from editing, as well as assessing 
the position and size of each indel for all of the PCR amplicons evaluated. Seven 
single cell samples processed solely for genotyping failed to amplify using any of 
the sgRNA2b on-target site primers. Eight samples from single cells processed 
using the modified G&T-seq protocol failed to amplify using any of the sgRNA2b 
on-target site primers. We further tested these DNA samples using primers up- and 
down-stream of the sgRNA2b on-target site. We also performed PCR analysis using 
primers targeting GAPDH as a positive control. These samples failed to generate 
amplicons using any of these primer pairs and were subsequently excluded from 
the analysis on the basis that they were likely to be of poor quality.
(2) For the samples used in the cytogenetic analysis described below, the cells 
were subjected to WGA (SurePlex, Rubicon). Out of the 22 OCT4-targeted human 
embryo samples, three failed WGA using this protocol and were excluded from 
further analysis and three showed suboptimal amplification. The samples showing 
some evidence of amplification were processed along with three control samples 
for genotype analysis. The resulting PCR amplicons were quantified using high 
sensitivity Qubit assay to establish whether concentrations were in an acceptable 
range (approximately 3–5 ng μ l−1). Gel electrophoresis confirmed that the size of 
the PCR product corresponded to the expected amplicon size. Of the 19 WGA 
products examined from the OCT4-targeted embryos, six failed the targeted PCR 
amplification and were excluded from further analysis. The rest were processed 
for genotype analysis using MiSeq targeted deep sequencing. The sequences were 
analysed using the CRISPR Cas Analyser tool by uploading the FASTQ files and 
defining the target DNA sequence and unedited sequence as a reference. The 
genotypes were further confirmed using the IGV software (Broad Institute).
The samples from the protocols above were used for genotyping of on- and 
putative off-target sites. The samples were amplified using the primers listed in 
Extended Data Table 1a. Primers were designed to generate amplicons of approxi-
mately 250 bp centred around the predicted cut site so as to maximize the detection 
of a variety of mutations and ensure that each amplicon was sequenced continu-
ously from the forward and reverse barcode. We excluded PCR primers targeting 
highly polymorphic regions of the genome35.
PCR amplification of the sgRNA2b on-target site was initially performed on 
all samples using a primer pair generating an amplicon size of 244 bp, which is 
also suitable for MiSeq analysis. Any samples that failed amplification three times 
using this primer pair were subjected to amplification using alternative primer 
pairs listed in Extended Data Table 1a. Where only the original reference genome 
sequence was identified, the genotype was classified as wild-type. When only edited 
sequences were detected, the genotype was defined as knockout. Whenever an 
original reference sequence and an edited sequence were identified in the same 
cell the corresponding cell was characterised as heterozygous. Where possible 
we assessed multiple single cells from the same embryo. Putative off-target sites 
were evaluated using the primer pairs listed in Extended Data Table 1a.
Evaluating potential off-target sites. Putative off-targets were determined using 
the MIT CRISPR Design tool (http://crispr.mit.edu/), which indicated top scoring 
off-target sites. We evaluated sequences that had mismatches of three nucleotides 
or fewer compared to the sgRNA2b sequence. As described previously17, potential 
off-target sites were also identified by using the following parameters: 12 base pairs 
of the sgRNA seed sequence plus an NGG PAM sequence where (N was varied 
to include all possible nucleotides) were searched against the reference human 
genome (hg19).
Digenome sequencing. Digenome-seq was performed as described previously15,16. 
In brief, 20 μ g genomic DNA was incubated with pre-incubated 100 nM recom-
binant Cas9 protein and 300 nM sgRNA in a reaction volume of 1 ml (100 mM 
NaCl, 50 mM Tris-HCl, 10 mM MgCl2, 100 μ g ml−1 BSA, pH 7.9) at 37 °C for 8 h. 
Digested DNA was mixed with 50 μ g ml−1 RNase A (Qiagen) at 37 °C for 30 min, 
and purified again with a DNeasy Tissue Kit (Qiagen). One micrgram of digested 
DNA was fragmented using the Covaris system and ligated with adaptors using 
TruSeq DNA libraries. DNA libraries were subjected to whole genome sequencing 
performed at Macrogen using an Illumina HiSeq X Ten at a sequencing depth of 
30–40× . In vitro DNA cleavage scores were calculated using a previously described 
scoring system16.
Immunohistochemistry. Embryos and cells were fixed with 4% paraformaldehyde 
in PBS for 1 h and overnight, respectively, at 4 °C and immunofluorescently 
 analysed as described previously2. The primary antibodies used are listed in 
Extended Data Table 1b. Embryos were placed on coverslip dishes (MatTek) for 
confocal imaging.
Cytogenetic analysis. To determine the chromosome copy number, single or 
multiple blastomeres were biopsied from embryos at the cleavage stage and 
clumps of approximately five cells were microdissected from the trophectoderm of 
blastocysts. The cells were washed through three drops of a wash buffer (PBS/0.1% 
polyvinyl alcohol), which had previously been tested to confirm absence of con-
taminating DNA (Reprogenetics UK). The cells were transferred to 0.2-ml PCR 
tubes in a volume of 1.5 μ l, lysed and subjected to whole-genome amplification 
(SurePlex, Rubicon) followed by low-pass next generation sequencing (coverage 
depth < 0.1× ) (VeriSeq PGS kit, Illumina). Libraries were prepared according 
to the manufacturer’s instructions and sequenced using the MiSeq sequencing 
platform. Typically, ~ 1 million reads were generated per sample, of which 60–70% 
successfully mapped to unique genomic sites. Mapped reads were interpreted using 
BlueFuse Multi software (Illumina) in order to generate chromosome copy number 
profiles. This strategy has been extensively validated and is widely used for the 
detection of whole chromosome losses and gains, as well as segmental aneuploidy, 
in human embryos undergoing preimplantation genetic diagnosis26. Analysis of 
single blastomeres allowed each chromosomal region of at least 5 Mb to be assigned 
a copy number of 0, 1, 2, 3 or 4 (corresponding to nullisomy, monosomy, disomy, 
trisomy or tetrasomy). In trophectoderm samples, composed of several cells, it was 
also possible to detect the presence of chromosomal mosaicism, indicated when 
copy number values for a given chromosome had an intermediate value, between 
the thresholds for assigning 1 and 2 or 2 and 3 chromosome copies41.
Imaging. Confocal immunofluorescence pictures were taken with a Leica SP5 
confocal microscope and 3–5-μ m-thick optical sections were collected. 
Quantification was performed manually using Fiji (ImageJ) or automated using 
MINS 1.3 software42.
Epifluorescence images were obtained on an Olympus IX73 using Cell^F 
software (Olympus Corporation) or on an EVOS FL cell imaging system 
(AMF4300). Phase contrast images and videos were collected on an Olympus 
IX73 using with Cell^F software and RI Viewer software (Research Instruments), 
respectively.
Time-lapse imaging was performed using an EmbryoScope+ time-lapse 
incubator (Vitrolife) and annotated using the EmbryoViewer software.
Generation of optimized inducible knockout (OPTiKO) human ES cell lines. 
The sgRNA sequences were cloned into the pAAV-Puro_siKO-TO vector as 
 previously described11. In brief, complementary single-stranded oligonucleotides 
(Extended Data Table 1a) were annealed and scarlessly ligated to AarI-digested 
plasmids between the H1-TO tetracycline-inducible promoters and the scaffold 
sgRNA sequence. The Cas9 and inducible sgRNA targeting vectors were each 
inserted into one of the two alleles of the AAVS1 locus by homologous-directed 
recombination facilitated by two obligate heterodimer ZFNs11. Cells were cultured 
in the presence of 10 μ M ROCK inhibitor Y-27632 (Sigma-Aldrich; Y0503) in 
medium without antibiotics 24 h before nucleofection. Cells were washed with PBS 
(Life Technologies; 14190-094) and dissociated with Accutase (Life Technologies; 
A11105-01) for 5 min at 37 °C. Colonies were mechanically triturated into clumps 
of 2–3 cells and counted. 2 × 106 cells were nucleofected in 100 μ l with a total 
of 12 μ g DNA (4 μ g each for the two ZFN plasmids, and 2 μ g each for the two 
targeting vectors) using the Lonza P3 Primary Cell 4D-Nucleofector X Kit and the 
cycle CA-137 on a Lonza 4D-Nucleofector System. Cells were incubated for 5 min 
at room temperature, after which antibiotic-free KSR containing 10 μ M ROCK 
inhibitor was added. After another 5 min the cell suspension was distributed 
on pre-plated DR4 (Applied Stem Cell; ASF-1013) drug resistant MEF feeders 
in antibiotic-free KSR medium. Four days after nucleofection, cells underwent 
double antibiotic selection with 0.5 μ g ml−1 Puromycin (Sigma-Aldrich) and 
25 μ g ml−1 Geneticin (G418 Sulphate (Gibco)) for 7 days. Targeted colonies 
appeared after 4–8 d and were mechanically picked and clonally expanded at 10–14 
d after transfection.
Extensive genotyping was carried out on the targeted clones to check for 
 correct AAVS1 gene targeting and to exclude the presence of randomly integrated 
plasmids, as previously described11. Briefly, genomic DNA was extracted using the 
Wizard Genomic DNA Purification Kit (Promega; A1120). Site-specific integration 
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was checked for both 5′ and 3′ ends of each of the two targeting vectors (Cas9 and 
inducible sgRNA). Clones were also screened for the absence of the wild-type locus 
(indicating homozygous targeting) and for the absence of amplicons for both the 
5′ and 3′ ends of the targeting vector backbones (to ensure there was no random 
integration of the plasmid).
Culture conditions for human ES cells and engineering inducible cell lines. 
Clonal H9 human ES cells (WiCell) (n = 2 or 3 per sgRNA) were cultured in 
feeder- and serum-free conditions either in mTeSR1 (Stem Cell Technologies) on 
growth factor-reduced Matrigel-coated dishes (BD Biosciences) or as previously 
described43 as indicated in the figure legends. Tetracycline hydrochloride (Sigma-
Aldrich; T7660) was used at 1 μ g ml−1 to induce guide expression. Human ES cells 
underwent routine mycoplasma screening and karyotyping.
Flow cytometry. Cells were collected every day for 5 d alongside matched control 
cells. Cells were dissociated into single-cell suspension using TrypLE Select 1X 
(Gibco; 12563011) for 5 min at 37 °C. The cell suspension was pelleted, washed 
with PBS (Life Technologies; 14190-094) then fixed and permeabilized using BD 
Cytofix/Cytoperm (554714) for 20 min at 4 °C. A 1×  permeabilization/wash buffer 
(BD; 554723) containing fetal bovine serum (FBS) and saponin was used for all 
subsequent wash steps and during antibody incubation unless indicated otherwise. 
After fixation, cells were washed once then stored at 4 °C until the day 5 sample 
had been collected, at which point all samples underwent intracellular staining. 
Cells were blocked for 30 min at room temperature with 1× permeabilization/wash 
buffer containing 10% donkey serum (Bio-rad; C06SB) and 0.1% Triton X-100 
(ThermoFisher Scientific; 85111). Cells were stained with primary antibodies by 
incubating at room temperature for 1 h and cells were washed three times after 
each incubation. Negative control secondary-only stained cells and unstained 
cells were performed on each batch of cells at a given day. Flow cytometry was 
performed using a Cyan ADP flow cytometer and the Summit software (Beckman 
Coulter), and 10,000–50,000 events were recorded. FlowJo was used to analyse flow 
 cytometry results. Cells were first gated on the basis of forward and side scatter 
properties, after which singlets were isolated on the basis of relationship between 
side scatter area peak area and width. A secondary-only negative control was used 
to determine the background and OCT4-positive cells were quantified relative 
to cells that were OCT4-negative in the total bulk population of cells analysed.
RNA isolation from human ES cells for RNA-seq and qRT–PCR. qRT–PCR data 
presented in Extended Data Fig. 1c were generated as follows: RNA was isolated 
using TRI reagent (Sigma) and DNase I-treated (Ambion). cDNA was synthe-
sized using a Maxima first strand cDNA synthesis kit (Fermentas). qRT–PCR was 
performed using SensiMix SYBR low-ROX kit (Bioline) on a QuantStudio 5 
machine (ThermoFisher Scientific). Primers pairs used are listed in Extended 
Data Table 1a. Each sample was run in triplicate and samples were normalized 
using GAPDH as the housekeeping gene, and the results were analysed using the 
Δ Δ Ct method
In preparation for RNA-seq of the human ES cells induced to express sgRNA2b, 
samples were further cleaned using ethanol precipitation. Libraries were prepared 
using KAPA mRNA HyperPrep kit for Illumina platforms (Roche Sequencing 
Solutions Inc.)
The qRT–PCR data presented in Extended Data Fig. 2b were generated as 
follows: RNA was extracted using the GenElute Mammalian Total RNA Miniprep 
Kit (Sigma-Aldrich; RTN350-1KT) and the On-Column DNase I Digestion 
kit (Sigma-Aldrich; DNASE70-1SET). Five-hundred nanograms of RNA was 
reverse-transcribed with SuperScript II (Invitrogen; 18064071). qRT-PCR was 
performed using 5 ng cDNA and SensiMix SYBR low-ROX (Bioline; QT625-20). 
qRT–PCR was performed on a Stratagene Mx-3005P (Agilent Technologies) 
and the results were analysed using the Δ Δ Ct method. Each sample was run in 
 duplicate and samples were normalized using PBGD as the housekeeping gene.
G&T-seq. Samples were processed using a previously published protocol that 
was adapted where indicated29. Single cells from microdissected human embryos 
were picked using 100 μ m inner diameter Stripper pipette (Origio) and trans-
ferred to individual low bind RNase-free tubes containing 2.5 μ l RLP plus buffer 
(Qiagen; 79216).
To separate RNA and genomic DNA (gDNA), 50 μ l of Dynabeads were washed 
and incubated with 100 μ M biotinylated poly-dT oligonucleotide (IDT). Ten micro-
litres of oligo-dT beads were added to each tube containing the single cell. Samples 
were incubated in a thermomixer for 20 min at room temperature at 2,000 r.p.m. 
Tubes were put on a magnet until the beads collected into a pellet and the super-
natant went clear. The supernatant containing the genomic DNA was transferred 
to a new collection tube. Beads were washed three times to collect any residual 
genomic DNA, which was amplified as described above.
cDNA was generated from the RNA captured on the bead using the SMARTer 
v4 Ultra Low Input kit (Clontech; 634891) as previously described3. Reverse 
transcription was performed on the thermomixer using the settings 2 min at 
42 °C at 2,000 rpm, 60 min at 42 °C at 1,500 rpm, 30 min at 50 °C at 1,500 rpm and 
10 min at 60 °C at 1,500 rpm. cDNA was amplified by adding 12.5 μ l 2X SeqAmp 
PCR buffer, 0.5 μ l PCR Primer II A (12 μ M), 0.5 μ l SeqAmp DNA polymerase, 
1.5 μ l nuclease-free water. Beads were mixed on a thermomixer for 60 s at room 
 temperature at 2,000 rpm and then were incubated on a PCR machine using the 
following settings: 95 °C for 1 min, 24 cycles of 98 °C for 10 s, 65 °C for 30 s and 68 °C 
for 3 min, before a final extension for 10 min at 72 °C. Amplified cDNA was purified 
by adding 25 μ l Ampure XP beads according to the manufacturer’s instructions. 
Twelve microlitres of purification buffer was added to rehydrate the pellet and 
 incubated for 2 min at room temperature. cDNA was eluted by pipetting up and 
down 10 times before returning the tube to the magnet. The clear supernatant 
containing the cDNA was removed from the immobilised beads and transferred to 
a new low-bind tube. cDNA was stored at − 80 °C until library preparation. cDNA 
quality was assessed by High Sensitivity DNA assay on an Agilent 2100 Bioanalyser 
with good quality cDNA showing a broad peak from 300 to 9,000 bp. cDNA 
concentration was measured using QuBit dsDNA HS kit (Life Technologies).
In preparation for library generation, cDNA was sheared using an E220 
focused-ultrasonicator (Covaris) to achieve cDNA in 200-500 bp range. Ten 
microlitres of cDNA sample and 32 μ l purification buffer was added to a Covaris 
AFA Fibre Pre-Slit Snap Cap microTUBE. cDNA was sheared using the following 
settings: Peak Incident power 175 W, Duty Factor 10%, 200 cycles per burst, water 
level 5.
Libraries were prepared using Low Input Library Prep Kit v2 (Clontech; 634899) 
according to manufacturer’s instructions. Dual indexing was performed by 
substituting the manufacturer’s provided indexing adaptors with NEBNext 
Multiplex Oligos for Illumina Dual Index primers set 1 (NEB; E7600S). Library 
quality was assessed by Bioanalyser and the concentration was measured by high 
sensitivity QuBit assay.
Twenty-five microlitres of AMPure beads was added to each collection tube con-
taining the genomic DNA. Tubes were mixed well and incubated at room tempera-
ture for 20 min so that the DNA could be bound to the beads. Tubes were put on the 
magnet until the supernatant ran clear so that it could be removed and discarded. 
The beads were washed twice with 100 μ l 80% ethanol. Any remaining ethanol was 
removed and beads allowed to dry, and resuspended in nuclease-free water.
Single-cell RNA-seq data analysis. RNA-seq data for single cells were obtained 
as paired-end reads and analysis was performed blinded to the identity of the 
samples. The RNA-Seq data flow was managed by a GNU make pipeline. Transcript 
reads were aligned to the Ensembl GRCh37 genome using TopHat2 (version 2.1.1 
with option no coverage search)44; alignment rates were typically between 60 
and 80%. Transcript counts were computed using the featureCounts program 
(version 1.5.1)45. A quality filter was applied to the matrix, ensuring > 50,000 total 
transcript reads per cell and > 5 reads in at least 5 samples. The raw transcript 
counts were corrected for read-count depth effects using the SCnorm package46 
with a single-group design matrix. The RUVSeq47 (version 1.10.0) was used for 
between-sample normalization by applying the ‘betweenLaneNormalization’ 
function with ‘full’ quantile regression. For PCA analysis, transcript counts were 
transformed using a asinh(x/2) transformation with per-gene centring to obtain 
near-Gaussian and zero-centred count distributions. The prcomp function of the 
stats package in R (version 3.4.1) was applied to the count matrix and single cells 
were projected into the plane of the first two eigenvectors.
Independently, sequenced reads from all single cell samples were also aligned to 
the human reference genome sequence GRCh38 using TopHat2 (version 2.1.1)44 
and parameters were optimized for 100-bp paired-end reads. Read counts per gene 
were calculated using the python package HTSeq (version 0.6.1)48 and differential 
gene expression analysis was carried out using DESeq2 (version 1.10.1)49. Read 
counts were normalized using the RPKM method50 and hierarchical clustering 
of samples was performed to generate a heat map using the R package pheatmap 
(version 1.0.8). A previously published reference control dataset3 was integrated 
in the heat map and hierarchical clustering. Principal components analysis was 
performed using the stats (version 3.2.2) R package on a previously published single 
cell RNA-seq dataset covering different stages of preimplantation development30 
together with our own OCT4-targeted samples and controls.
The scripts used to generate the figures have been deposited in GitHub and can be 
accessed using the following link: https://github.com/Genalico/RNAseq-BlaCy_pub. 
The read-depths for each sample are provided in Supplementary Table 2 and via 
the above GitHub link.
Data availability. Source Data are provided for figures. MiSeq and RNA-seq data 
have been deposited into Gene Expression Omnibus (GEO) under accession 
numbers GSE100119 and GSE100120, respectively. Scripts used for bioinformatics 
 analysis can be found on the following GitHub page: https://github.com/Genalico/
RNAseq-BlaCy_pub. Any additional information is available upon request from 
the  corresponding author.
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Extended Data Figure 1 | POU5F1 targeting and comparison of sgRNAs. 
a, Schematic representation of the human POU5F1 locus and sgRNA 
targeting sites. The location (not to scale) and sequences of the sgRNAs 
tested are shown and the PAM sequences are underlined and in red font. 
Sequences within the exons are in uppercase and introns are in lowercase. 
The mouse sgRNA sequences are shown below. The exons encoding the 
N-terminal domain (NTD), POU DNA-binding domain or the C-terminal 
domain (CTD) are indicated. b, Representative flow cytometry analysis 
quantifying OCT4 expression in human ES cells induced to express each 
sgRNA over 5 days compared to uninduced controls. The percentage of 
OCT4 protein expression is shown. c, qRT–PCR analysis after 4 days of 
sgRNA induction in mTeSR medium. Relative expression reflected as fold 
difference over uninduced cells normalized to GAPDH. Data points and 
mean for all samples are shown: n = 2 sgRNA1-1 clones; n = 3, sgRNA 1-2, 
2b or 4 clones, representative of two independent experiments and ± s.e.m. 
where there are three samples. Two-way ANOVA; * P < 0.05; * * P < 0.01; 
* * * P < 0.001; * * * * P < 0.0001. d, Heat maps of selected genes showing 
unsupervised hierarchical clustering of uninduced and sgRNA2b-induced 
human ES cells. Normalized RNA-seq expression levels are plotted on a 
high-to-low scale (purple–white–green).
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Extended Data Figure 2 | Further characterization of sgRNA2b-induced 
human ES cells. a, Human ES cells induced to express sgRNA2b for 4 days 
(+ Tet) in chemically defined medium with activin A and FGF2 (CDM/AF)  
compared to uninduced controls (No Tet). Immunofluorescence analysis 
for the pluripotency markers OCT4, NANOG and SOX2 or markers 
associated with differentiation to early derivatives of the germ layers 
(SOX1-expressing ectoderm cells or SOX17-expressing endoderm  
cells). DAPI nuclear staining (blue) is shown. Scale bars, 400 μ m.  
b, qRT–PCR analysis for selected genes associated with either pluripotency 
or differentiation to derivatives of the germ layers in human ES cells 
induced to express each of the sgRNAs for 4 days. Relative expression 
reflected as fold difference over wild-type human ES cells and normalized 
to PBGD. Data points and mean ± s.e.m. are shown: n = 3 wild-type H9 
and sgRNA2b, representative of two independent experiments. Two-way 
ANOVA; * P < 0.05; * * P < 0.01; * * * P < 0.001; * * * * P < 0.0001, ns, not 
significant.
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Extended Data Figure 3 | On-target mutation spectrum in human ES cells 
induced to express sgRNA1-1, sgRNA1-2, sgRNA2b or sgRNA4. Shown 
are frequent types of indel mutations and corresponding sequences observed 
in human ES cells induced to express sgRNA1-1, sgRNA1-2, sgRNA2b or 
sgRNA4. The cells were induced to express each sgRNA for 4 days and the data 
shown are representative of the types of indel mutations observed in other 
clonal lines (n = 2 sgRNA1-1 clones; n = 3, sgRNA 1-2, 2b or 4 clones) and 
across time (from 1 to 4 days following induction of each sgRNA).
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Extended Data Figure 4 | See next page for caption.
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Extended Data Figure 4 | Off-target analysis of sgRNA2b-induced 
human ES cells. a, The POU5F1 sgRNA2b 12-bp seed sequence is 
highlighted in green and the NGG PAM sequence in red. In black are 
the nucleotide sequences 5′ to the sgRNA seed sequence. Seven putative 
off-target sequences and associated genes are shown including POU5F1 
pseudogenes. In orange are the nucleotides that differ from the sgRNA2b 
sequence. b, Percentage of indel mutations detected at putative off-target 
sites in human ES cells 4 days after tetracycline induction of sgRNA2b 
compared to uninduced controls. Data are percentages of indel mutations 
detected by targeted deep sequencing in the cell lines at each of the sites 
indicated. Comparisons made between three clonal human ES cell lines 
induced to express sgRNA2b versus uninduced controls. The percentage 
of indel mutations induced at the on-target site were significantly different 
while all other sites were not significantly different. Two-way ANOVA.  
* * * P < 0.001. c, Digenome-seq results displayed as a genome-wide  
circos plot. The height of the peak corresponds to the DNA cleavage  
score. The red arrow points to the POU5F1 locus on chromosome 6.  
d, Percentage of indel mutations observed in sgRNA2b-induced human 
ES cells and in wild-type H9 control cells at each locus following targeted 
deep sequencing of putative off-target sites identified by Digenome-seq. 
e, Off-target candidate nucleotides displayed as sequence logos using 
the WebLogo program. f, Percentage of indel mutations observed in 
sgRNA2b-induced human ES cells and in wild-type H9 control cells 
following targeted deep sequencing of putative off-target sites determined 
by WebLogo sequence homology.
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Extended Data Figure 5 | Assessing a range of Cas9 and sgRNA 
combinations for microinjection into mouse pronuclear zygotes.  
a, b, Additional conditions were tested in mouse embryos microinjected 
with the sgRNA2b either with Cas9 mRNA (a) or as a complex with the 
Cas9 protein (b) at the ratios indicated. Quantification was performed 
on the proportion of mouse embryos at the blastocyst stage that are 
phenotypically null (loss of OCT4 and SOX17 protein expression), mosaic 
or heterozygous (partial OCT4 and/or SOX17 expression) or uninjected 
(strong OCT4 and SOX17 expression). Data are mean ± s.d. from  
three independent experiments. Comparisons were made between  
the percentage of OCT4-null embryos observed versus wild-type 
uninjected control embryos. Chi-squared test. * P < 0.05; * * * P < 0.001;  
* * * * P < 0.0001. c, The types of indel mutations detected in mouse 
embryos microinjected with the sgRNA2b–Cas9 complex. The sgRNA 
sequence is boxed and the NGG PAM site underlined. Dash, deletion 
position. d, Further characterization of mouse embryos microinjected 
with sgRNA2b–Cas9 compared to uninjected control blastocysts. 
Immunofluorescence analysis for markers of the trophectoderm (CDX2) 
or primitive endoderm (GATA4, GATA6, PDGFRA and SOX7) lineages 
together with DAPI nuclear staining. Confocal z-section. Scale bars,  
100 μ m. e, Quantification of blastocyst inner cell mass (ICM) or 
trophoblast outgrowths in mouse embryonic stem cell derivation 
conditions. Uninjected, Cas9-injected or Cas9 plus Dmc1 sgRNA-injected 
cells (targeting a gene not essential for preimplantation development)  
were used as controls. Comparisons were made between the percentage 
of ICM outgrowths observed in blastocysts that developed following 
sgRNA2b–Cas9 microinjection. Two-tailed t-test. * P < 0.05.
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Extended Data Figure 6 | Further assessing human embryo quality.  
a, Karyotype analysis following whole-genome sequencing of either single 
blastomeres, a clump of three cells from a cleavage stage embryo or a 
clump of 3–5 cells from trophectoderm biopsies. Multiple biopies were 
analysed from embryos C8, C12 and C16. Analysis was also performed 
on blastocysts that developed following microinjection of Cas9 protein. 
The type of chromosome gains and losses are indicated. b, Representative 
karyotype analysis by whole-genome sequencing of human blastocysts. 
A representative graph indicating aneuploidy in embryos following Cas9 
protein and sgRNA2b–Cas9 ribonucleoprotein complex microinjection. 
c, Phase-contrast images of starting blastocysts and blastocysts that 
developed following microinjection of the sgRNA2b–Cas9 complex 
compared to Cas9 protein-injected controls. White arrows point to the 
presumptive inner cell mass and a black arrow to a representative zona 
pellucida.
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Extended Data Figure 7 | Evaluating on-target and putative off-target 
mutations in human embryo cells. a, The type and relative proportion 
of indel mutations observed compared to all observable indel mutations 
within each human embryo. b, Quantification of indels by TIDE analysis. 
Representative plots and Sanger sequencing chromatograms are shown 
from OCT4-null, heterozygous and wild-type human cells. c, Percentage 
of indel mutations detected at the sgRNA2b on-target site and putative off-
target sites in single cells microdissected from Cas9 protein-microinjected 
control blastocysts or blastocysts that developed following sgRNA2b–Cas9 
complex microinjection. Putative off-target sites were evaluated in cells 
that were previously determined to be OCT4-null (green), heterozygous 
(orange) or wild-type (blue) along with samples from Cas9 protein-
microinjected embryos (red). Three representative examples of wild-type 
and edited cells are shown. d, Sanger sequencing chromatograms from 
OCT4-null single cells collected from human blastocysts that developed 
following sgRNA2b–Cas9 microinjection. The chromatograms exemplify 
the sequence detected in all of the other samples analysed. Underlined is 
the sequence of the putative off-target site.
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Extended Data Figure 8 | Phenotypic characterization of OCT4-
targeted embryos. a, Immunofluorescence analysis for OCT4 (green) and 
DAPI nuclear staining (blue) in human cleavage stage embryos following 
sgRNA2b–Cas9 complex microinjection (n = 5). Confocal z-section. 
Arrow, OCT4-expressing cell. Scale bars, 100 μ m. b, Immunofluorescence 
analysis for OCT4 (green), SOX17 (red) and DAPI nuclear staining (blue) 
in an uninjected control blastocyst (n = 3) or a human blastocyst that 
developed following sgRNA2b–Cas9 complex microinjection (n = 3). 
Confocal z-section. Scale bars, 100 μ m. c, d, Immunofluorescence analysis 
for OCT4 (green), NANOG (red) and DAPI nuclear staining (blue) in 
a human blastocyst that developed following sgRNA2b–Cas9 complex 
microinjection (c, n = 3) or in a mouse uninjected control blastocyst 
or in blastocysts that developed following sgRNA2b–Cas9 complex 
microinjection (d, n = 7). Confocal z-section. Scale bars, 100 μ m.  
e, Quantification of NANOG and OCT4 expression in mouse uninjected 
control blastocysts (n = 5) or in blastocysts that developed following 
sgRNA2b–Cas9 complex microinjection (n = 7). One-tailed t-test.  
* * P < 0.01. f, Immunofluorescence analysis for GATA2 (green) and  
DAPI nuclear staining (blue) in a human blastocyst that developed 
following sgRNA2b–Cas9 complex microinjection (n = 3). Confocal 
projection. Scale bar, 100 μ m.
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Extended Data Figure 9 | Transcriptome analysis of OCT4-targeted 
embryos. a, Hierarchical clustering and heat map of a selection of genes 
following single-cell RNA-seq analysis of human embryos. Embryos C8, 
C9, C12 and C16 (samples denoted in orange font) were targeted with the 
sgRNA2b–Cas9 complex. Embryos 2, 5, 7 and 8 were microinjected with 
Cas9 protein as a control. An uninjected control reference dataset labelled 
PE (primitive endoderm cells), EPI (epiblast cells) or TE (trophectoderm 
cells) is included3. Control cells clustered according to lineage and are 
indicated with the coloured bars: red, primitive endoderm; green, epiblast; 
and blue, trophectoderm. Grey bar highlights the samples that have low 
expression of markers of each of the lineages shown. The genotypes of 
the samples are noted as POU5F1 wild-type (WT), heterozygous (Het) 
or knockout (KO). Five samples failed repeated genotyping but the RNA 
quality is good and these are listed as X. Normalized expression levels 
are plotted on a high–low scale (purple–white–green). b, c, Principal 
component analysis of a previously published human single-cell RNA-seq  
dataset30 integrated with the data from the Cas9 protein control and 
the sgRNA2b–Cas9 ribonucleoprotein (RNP) complex-microinjected 
embryos. Each point represents a single cell. Data were plotted along the 
second and third (b) or the first and third (c) principal components.
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extended data table 1 | Reagent list
a, Oligonucleotides used for cloning, Sanger sequencing, MiSeq or qRT–PCR analysis. b, Antibodies used for immunofluorescence and flow cytometry analysis.
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    Experimental design
1.   Sample size
Describe how sample size was determined. The R statistical package pwr was used to determine the number of human 
embryos required to determine the function of OCT4 compared to microinjected 
controls. A two-sample t-test was performed to a significance level of 0.05 p-value. 
The effect size was 0.8 which assumes an observable difference between the 
CRISPR injected and control embryos. Sample size was estimated to be 25 CRISPR-
targeted embryos.
2.   Data exclusions
Describe any data exclusions. No data was excluded from the analyses.
3.   Replication
Describe whether the experimental findings were 
reliably reproduced.
Yes attempts at replication were successful.
4.   Randomization
Describe how samples/organisms/participants were 
allocated into experimental groups.
Randomization was not performed in our studies.
5.   Blinding
Describe whether the investigators were blinded to 
group allocation during data collection and/or analysis.
The computational analysis of cell lines and human embryos was performed blind 
to the identity of the samples.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
6.   Statistical parameters 
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the 
Methods section if additional space is needed). 
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same 
sample was measured repeatedly
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one- or two-sided (note: only common tests should be described solely by name; more 
complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted
A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
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   Software
Policy information about availability of computer code
7. Software
Describe the software used to analyze the data in this 
study. 
The TIDE, CRISPR Genome Analyser or CRISPR Cas Analyser tools were used to 
estimate the percentage, position and size of indels for each of the PCR amplicons 
evaluated. We used Prism (7.0) for the qRT-PCR analysis. We used TopHat, Bowtie2 
and DESeq2 for the RNA-seq analysis. We used FlowJo (10.0.7) for flow cytometry 
analysis.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made 
available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for 
providing algorithms and software for publication provides further information on this topic.
   Materials and reagents
Policy information about availability of materials
8.   Materials availability
Indicate whether there are restrictions on availability of 
unique materials or if these materials are only available 
for distribution by a for-profit company.
There are no restrictions on availability of the material and we are happy to share 
all of the materials freely.
9.   Antibodies
Describe the antibodies used and how they were validated 
for use in the system under study (i.e. assay and species).
This information is included in Extended Data Table 1 and other details are in the 
methods section.
10. Eukaryotic cell lines
a.  State the source of each eukaryotic cell line used. The H9 cell line was obtained under licence and SLA agreement with WiCell.
b.  Describe the method of cell line authentication used. The H9 cell line has been exhaustively tested include STA profiling, karyotpying, 
gene expression, etc.
c.  Report whether the cell lines were tested for 
mycoplasma contamination.
The cell lines were tested for mycoplasma and were found to be negative 
d.  If any of the cell lines used are listed in the database 
of commonly misidentified cell lines maintained by 
ICLAC, provide a scientific rationale for their use.
No.
    Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
11. Description of research animals
Provide details on animals and/or animal-derived 
materials used in the study.
All animal research was performed in compliance with the UK Home Office Licence 
Number 70/8560. 4-8 week old B6CBF1 mice were used.
Policy information about studies involving human research participants
12. Description of human research participants
Describe the covariate-relevant population 
characteristics of the human research participants.
This is not applicable as we used donated embryos surplus to IVF treatment.
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In this Article, the received date appeared wrongly in the advance 
online publication (AOP) version as 12 June 2016 rather than 12 June 
2017. This error was corrected online on 22 September 2017; the print 
version is also correct.
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